The study observed people with endometrial cancer from seven different countries and the size of the tumor was reduced in 42% of the population studied.Dostarlimab exhibits better efficacy than other PD-1 inhibitors, such as avelumab and durvalumab, in dMMR advanced endometrial cancers. Efficacy of the drug is measured by the response rate, which is 47% for dostarlimab. History
In 2020, dostarlimab, a PD-1inhibitor, was undergoing phase I/II and phase III clinical trials.In 2020, the manufacturer, Tesaro, announced preliminary successful results from the phase I/II GARNET study.In 2020, the GARNET study announced that dostarlimab had promising potential to treat a specific subset of individuals with recurrent or advanced endometrial cancer.In April 2021, dostarlimab was approved for the treatment of recurrent or advanced endometrial cancer with mismatch repair deficient (dMMR), which are genetic abnormalities that disrupt DNA repair, in individuals who had previously been treated with platinum-containing regimens.In April 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GSK). Efficacy was evaluated based on cohort (A1) in GARNET Trial (NCT02715284), a multicenter, multicohort, open-label trial in participants with advanced solid tumors.In 2022, an early clinical study of dostarlimab reported a 100% remission rate in 14 patients with rectal cancer who had mismatch repair deficiency, a type of genetic mutation that only affects 5-10% of cases. Society and culture
Dostarlimab is the international nonproprietary name (INN), and the United States Adopted Name (USAN).
Side effects
Serious adverse reactions in >2% of patients included sepsis, acute kidney injury, urinary tract infection, abdominal pain, and fever (pyrexia).Immune-mediated adverse reactions can occur including pneumonitis, colitis, hepatitis, endocrine disease (endocrinopathies), and nephritis.The most common side effects reported while taking this medication during a trial were dyspnea, asthenia, fatigue, and nausea.Symptoms of overdose are similar to the side effect profile of the medication, so it could involve significant immune-mediated reactions. Immune-mediated adverse reactions
Dostarlimab is a monoclonal antibody that binds to PD-1 to block it from binding PD-1 ligands to remove inhibition of immune response. With this, it causes risk for immune-mediated adverse reactions. These reactions can be severe or fatal and occur in any part of the body: organs or tissues.Examples of immune-mediated adverse reactions include immune-mediated pneumonitis, colitis, hepatitis, adrenal insufficiency, hypophysitis, thyroid disorders, nephritis with renal dysfunction, and dermatologic reactions. Pregnancy and lactation
Dostarlimab can cause harm to a fetus. The death of the fetus can occur from the immune systems reaction to the fetus through the examination of its mechanism in animal studies. Dostarlimab is a human immunoglobulin G (IgG4), which could permeate through the placental barrier. This may risk harm to the developing fetus as the drug may be passed on from the mother.Data is not available regarding the presence of dostarlimab in breastmilk. Hepatotoxicity
Dostarlimab causes mild to moderate elevations to serum aminotransferase and alkaline phosphatase in 15-25% of recipients. Serum ALT elevation above five times the normal range occurs in 2-3% of recipients.